Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis” [Genes & Diseases 11 (2024) 479–494]

• Yanran Bi,
• Ruiling Zheng,
• Jiahao Hu,
• Ruiqing Shi,
• Junfeng Shi,
• Yutao Wang,
• Peng Wang,
• Wenyi Jiang,
• Gyudong Kim,
• Zhiguo Liu,
• Xiaokun Li,
• Li Lin

Affiliations

Yanran Bi

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China; College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea

Ruiling Zheng

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China

Jiahao Hu

Department of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou 325000, China

Ruiqing Shi

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China

Junfeng Shi

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China

Yutao Wang

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China

Peng Wang

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China

Wenyi Jiang

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China

Gyudong Kim

College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea; Corresponding author.

Zhiguo Liu

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China; Corresponding author.

Xiaokun Li

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China; Corresponding author.

Li Lin

School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China; Zhejiang Lab for Regenerative Medicine, Oujiang Laboratory, Wenzhou 325035, China; Corresponding author. School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.